Inceptionr LLC Grows Stock Position in Amgen Inc. $AMGN

Inceptionr LLC grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 124.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,095 shares of the medical research company’s stock after purchasing an additional 1,714 shares during the quarter. Inceptionr LLC’s holdings in Amgen were worth $1,013,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Capital Wealth Planning LLC increased its holdings in Amgen by 75.2% in the 4th quarter. Capital Wealth Planning LLC now owns 1,447,173 shares of the medical research company’s stock worth $473,868,000 after acquiring an additional 621,393 shares in the last quarter. Renaissance Group LLC increased its holdings in Amgen by 25.7% in the 4th quarter. Renaissance Group LLC now owns 112,882 shares of the medical research company’s stock worth $36,947,000 after acquiring an additional 23,056 shares in the last quarter. Gilpin Wealth Management LLC purchased a new stake in Amgen in the 4th quarter worth approximately $1,374,000. Dorsey & Whitney Trust CO LLC increased its holdings in Amgen by 0.4% in the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 10,309 shares of the medical research company’s stock worth $3,374,000 after acquiring an additional 37 shares in the last quarter. Finally, Smithbridge Asset Management Inc. DE purchased a new stake in Amgen in the 4th quarter worth approximately $458,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen’s obesity drug MariTide is drawing attention as a potential growth driver, with analysts noting that its less frequent dosing could help the company compete in the fast-growing GLP-1/obesity market. Article Title
• Positive Sentiment: Amgen’s broader growth pipeline is being viewed as a potential offset to patent-related pressure, with some commentary suggesting 2026 could be a “springboard” year if newer drugs gain traction. Article Title
• Neutral Sentiment: Goldman Sachs trimmed its price target on Amgen but kept a Buy rating, signaling some caution on valuation while still seeing upside potential. Article Title
• Neutral Sentiment: Recent market commentary noted that Amgen has underperformed some peers and posted a bigger drop than the broader market, reflecting short-term profit-taking and weaker relative momentum. Article Title
• Negative Sentiment: Market coverage also flagged that Amgen fell more than the market in the latest session, reinforcing concern that investors may be locking in gains after the stock’s strong multi-year run. Article Title

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.85% of the company’s stock.

Amgen Trading Down 2.0%

Shares of AMGN opened at $337.73 on Thursday. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. Amgen Inc. has a 1 year low of $267.83 and a 1 year high of $391.29. The company has a 50 day simple moving average of $340.89 and a two-hundred day simple moving average of $345.53. The firm has a market cap of $182.28 billion, a P/E ratio of 23.50, a price-to-earnings-growth ratio of 3.46 and a beta of 0.42.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. During the same period last year, the firm posted $4.90 EPS. The company’s revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, equities analysts expect that Amgen Inc. will post 22.38 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently issued reports on AMGN. Freedom Capital raised shares of Amgen from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Cantor Fitzgerald reissued a “neutral” rating and issued a $350.00 target price on shares of Amgen in a report on Wednesday, April 8th. Jefferies Financial Group assumed coverage on shares of Amgen in a report on Tuesday, March 10th. They set a “hold” rating and a $350.00 price objective for the company. Royal Bank Of Canada increased their price objective on shares of Amgen from $360.00 to $370.00 and gave the company an “outperform” rating in a report on Tuesday, April 7th. Finally, Canaccord Genuity Group assumed coverage on shares of Amgen in a report on Monday, April 20th. They set a “hold” rating and a $366.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $354.12.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.